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Introduction
Platelets are essential for hemostasis but growing evidence indicates that platelets are involved in cancer metastasis and/or progression [1] . Several studies have reported that tumor cell-induced platelet aggregation protects vessels and tumor cell nests from immune cells or shear stress, and released growth factors promote angiogenesis or tumor growth [2] [3] [4] . Tumor cells activate platelets through numerous mechanisms, including direct cell-cell interactions and secretion of platelet-activating molecules, including adenosine diphosphate and thrombin [5, 6] . Some tumor cells use podoplanin, a transmembrane sialoglycoprotein, to activate platelets [7] . Podoplanin is present on the surface of certain tumor cells, including melanoma, squamous cell carcinoma, seminoma and brain tumor cells [7] [8] [9] . Increased levels of podoplanin are associated with tumor metastasis or malignant progression [10] . Therefore, podoplanin is a promising target for anti-metastatic therapy.
We identified platelet-activating C-type lectin-like receptor-2 (CLEC-2) as a receptor for the platelet-activating snake venom, rhodocytin [11] , and found that podoplanin is an endogenous CLEC-2 ligand [12] . In humans, CLEC-2 is exclusively present in platelets and megakaryocytes. However, in mice, CLEC-2 is produced by some immune cells, including dendritic cells, peripheral neutrophils, inflammatory macrophages, natural killer (NK) cells and B cells [13] , in addition to platelets and megakaryocytes. CLEC-2 is involved in thrombosis and hemostasis [14, 15] . May et al. used CLEC-2-deficient mice generated by immunodepletion to show that CLEC-2 is involved in thrombus stabilization in blood under flow [14] . Moreover, we previously used bone marrow chimeric mice transplanted with fetal liver cells from CLEC-2-deficient embryos to show that CLEC-2 is involved in thrombus stabilization, probably through homophilic interactions between two CLEC-2 molecules [16] . Bender et al. reported that a combined in vivo depletion of collagen receptor glycoprotein VI (GPVI) and CLEC-2 severely compromised hemostasis and abrogated arterial thrombosis in mice [15] . However, CLEC-2 deletion alone did not induce bleeding [16, 17] . Podoplanin is also produced by lymphatic endothelial cells and promotes blood and lymphatic vessel separation in a CLEC-2-dependent manner during development [18] . The CLEC-2/podoplanin axis is also important for high endothelial vascular integrity in the immune response [19] .
Tumor cell-induced platelet aggregation through CLEC-2-podoplanin interaction facilitates hematogenous tumor metastasis. We previously observed that experimental hematogenous metastasis of podoplanin-producing CHO cells significantly decreased after treatment with rat anti-mouse podoplanin monoclonal antibody, NZ-1 [20] . However, this does not rule out the possibility of a functional podoplanin receptor, besides CLEC-2, on the platelet surface. Inhibitory effects of the CLEC-2 blockade on hematogenous tumor metastasis should be determined to verify the role of CLEC-2 in tumor metastasis. Moreover, it is unclear whether CLEC-2 is involved in tumor growth and the overall survival of tumor-bearing animals.
In the present study, we generated an immunologically CLEC-2-depleted mouse model by using a rat anti-mouse CLEC-2 monoclonal antibody, 2A2B10, and investigated the role of CLEC-2 in hematogenous tumor metastases, tumor growth and survival of mice bearing podoplaninproducing B16F10 melanoma cells. We found that CLEC-2 depletion suppressed experimental hematogenous tumor metastasis and tumor growth in vitro but did not suppress tumor growth in vivo. Furthermore, CLEC-2 depletion suppressed thrombus formation in the lungs and subsequently improved the prognosis of tumor-bearing mice. These results suggest that CLEC-2 may be a useful target for designing anti-hematogenous metastatic drugs to prevent tumor metastasis and thrombosis, prolonging the survival of cancer patients.
Materials and methods

Cell lines and animals
Mouse B16F10 melanoma cells, green fluorescent proteintransfected B16F10 cells (B16F10-GFP) and 7-week-old male C57BL/6 mice were obtained from Cell Resource Center for Biomedical Research, Tohoku University (Miyagi, Japan), AntiCancer Japan (Chiba, Japan) and Charles River Japan (Kanagawa, Japan), respectively. CLEC-2-null mice (CLEC-2
À/À
) and megakaryocyte-and platelet-specific conditional CLEC-2-deficient mice (CLEC-2 flox/flox ; Pf4-Cre) were generated as described previously [16, 21] . This study was approved by the Animal Care and Use Committee at the University of Yamanashi.
Generation of 2A2B10 antibody
The monoclonal antibody, 2A2B10, was prepared by the Cell Engineering Corporation (Osaka, Japan). Recombinant mouse CLEC-2-rabbit Fc2 (mCLEC-2-rFc2) fusion protein was prepared as described previously [12] . A CLEC-2-reactive antibody-producing hybridoma, 2A2B10, was selected by immunizing rats with mCLEC-2-rFc2 by flow cytometry and western blotting. After culturing the hybridomas in hybridoma-SFM medium (Thermo Fisher Scientific, Waltham, MA, USA) for 2 weeks, monoclonal antibodies were purified by ammonium sulfate precipitation and HiTrap SP HP column chromatography (GE Healthcare, Little Chalfont, Buckinghamshire, UK).
Platelet preparation
Washed platelets were prepared using acid citrate dextrose solution and prostaglandin I 2 , and resuspended in calcium-free Tyrode's buffer as described [21] .
Western blotting
Western blotting was performed as described [21] . Briefly, washed platelets from CLEC-2 +/+ , CLEC-2 +/À or CLEC-2 À/À mice were lysed in Lithium Dodecyl Sulfate sample buffer (Life Technologies). Primary tumors were lysed in Radioimmunoprecipitation assay buffer (1 g mL
À1
) with complete protease inhibitor cocktail (Roche, Basel, Switzerland). Samples were separated by 4-12% SDS-PAGE and western blotted with 2A2B10, anti-mouse CD41 (Abcam, Cambridge, MA, USA; Clone, MW Reg30) or anti-mouse b-actin (LI-COR Bioscience, Lincoln, NE, USA).
Flow cytometry
To analyze platelets, blood was drawn from tail veins after intraperitoneal (i.p.) injection of 2A2B10 or control rat IgG antibody at the indicated time-points. Blood collection was performed as described previously [22] . Platelets were selected by staining with anti-CD41-Alexa Fluor 546 antibody (BD Bioscience, San Jose, CA, USA). CLEC-2 was detected with 2A2B10-Alexa Fluor 488 or control rat IgG-Alexa Fluor 488 antibodies. Other platelet receptors were analyzed by staining with direct-labeled antibodies, anti-GPVI-fluorescein isothiocyanate (FITC) (Emfret, Eibelstadt, Germany), anti-GPIba-phycoerythrin (PE) (Emfret), anti-integrin a2-PE (BD Bioscience) and anti-integrin b3-PE (BD Bioscience), or isotype control, 4 days after 2A2B10 injection.
For peripheral neutrophils, blood was drawn 4 days after 2A2B10 injection. Red blood cells were lysed in ammonium-chloride-potassium (ACK) buffer and neutrophils were then selected with anti-Gr-1-allophycocyanin (APC) antibody (BD Bioscience). For inflammatory lymphocytes, 100 lg Escherichia coli lipopolysaccharide was injected i.p. into mice 3 days after 2A2B10 injection. After 24 h, peripheral blood mononuclear cells were isolated from whole blood by centrifugation using a 1.083 g mL
À1
Percoll gradient. NK cells and B cells were selected with anti-CD3-FITC and anti-NK1.1-PE antibodies (BD Bioscience), and anti-CD45R/B220-APC antibodies (BD Bioscience), respectively. For inflammatory macrophages, peritoneal macrophages were collected 4 days after i.p. injection of thioglycollate medium into mice in addition to 2A2B10, and were selected using anti-F4/80-Alexa Fluor 546 (BD Bioscience). CLEC-2 levels in leukocytes were assessed with Alexa Fluor 488-labeled or Alexa Fluor 647-labeled 2A2B10, or control rat IgG antibodies.
To analyze the neutralizing activity of 2A2B10, peripheral neutrophils were incubated with 10 lg mL À1 2A2B10
or control antibodies and samples were then incubated with 20 lg mL À1 mouse podoplanin-rabbit Fc2 (mPodrFc2) fusion protein or rabbit Fc2 protein [12] . Neutrophil-bound proteins were detected with anti-rabbit IgG-Alexa Fluor 488 antibodies. Antibody binding was analyzed by BD Accuri C6 cytometry (BD Bioscience).
Antibody-induced CLEC-2 depletion in vivo
Control rat IgG (Molecular Innovations, Novi, MI, USA) or 2A2B10 (8 lg g À1 body weight) was administered i.p. into mice. Hematological observation was performed as described [22] . CLEC-2 levels were analyzed by flow cytometry. For sustained CLEC-2 deficiency, 2A2B10 was administered i.p. to mice on a weekly basis.
Hematogenous metastasis model B16F10-GFP cells (1 9 10 6 ) were resuspended in 200 lL phosphate buffered saline (PBS) and injected intravenously (i.v.) into mouse tail veins 4 days after the initial antibody injection. Mice were sacrificed 14 days after tumor injection and their lungs were collected. GFP fluorescence intensity in the lungs was measured using the IVIS Lumina imager (Perkin Elmer, Waltham, MA, USA) and the lungs were subsequently weighed.
Measurements of circulating tumor cells
Mice were anesthetized with chloral hydrate (400 mg kg À1 body weight). The ventral skin of the ear was cut along the antihelix of the pinna. Blood flow in the exposed ear vessels was recorded for 10 min using a fluorescence microscope (IX-71; Olympus, Tokyo, Japan) with attached CCD camera. GFP-positive circulating tumor cells (CTCs) were counted manually.
Tumor growth in vitro B16F10 cells (2 9 10 4 ) were seeded into six-well plates and incubated for 24 h at 37°C. Next, the cells were cocultured with or without washed mouse platelets (1 9 10 3 lL À1 to 1 9 10 5 lL À1 ) from CLEC-2 flox/flox , wild-type (WT), CLEC-2 flox/flox , Pf4-Cre (KO) mice, control IgG-injected mice or 2A2B10-injected mice, or with activated platelet supernatants (APS) [23] or recombinant CLEC-2 for 48 h. Live cells were counted using a TC-10 cell counter (Bio-Rad, Hercules, CA, USA) after trypan blue dye exclusion assay.
Tumor growth in vivo B16F10-GFP cells (1 9 10 6 ) were resuspended in 100 lL PBS and injected subcutaneously (s.q.) into the right hind flank of mice. Tumor volumes (Tv) were evaluated weekly, over 21 days after tumor injection, by direct caliper measurements, and calculated as Tv = (length 9 width 2 )/2.
Immunohistostaining
Primary tumors were harvested from mice 14 days after tumor injection. Functional vessels were identified by tail vein injection of 1 mg FITC-labeled dextran (MW 2000 kDa; Sigma-Aldrich, St. Louis, MO, USA) 10 min before sacrifice. Tumors were fixed in 10% formalin, equilibrated in 30% sucrose in PBS, and then embedded in Optimal Cutting Temperature compound (Sakura Finetek, Tokyo, Japan). Frozen tumor blocks were sliced into 5-lm-thick sections. Tumor vessels and thrombus formation were identified using rabbit anti-CD34 (Abcam), rat anti-CD41 (Abcam), sheep anti-fibrin/fibrinogen (Bio-Rad) and Alexa Fluor-conjugated secondary antibodies. Images were captured using a BioRevo fluorescence microscope (Keyence, Osaka, Japan) or by LSM-10 laser confocal microscopy (Olympus). Tumor vessels, functional vessels and fibrin/fibrinogen-filled vessels were counted manually. Lung sections were prepared as described above. Determination of fibrin/fibrinogen fluorescence intensity with ImageJ was utilized to assess fibrin clots in the lungs.
Survival analysis
B16F10-GFP cells (1 9 10 6 ) were injected s.q. into the right hind flank of mice. Survival was monitored over a 30-day period after tumor injection. Blood counts were determined at 21 days after tumor injection as described above. Plasma inflammatory cytokine levels were measured at 21 days after tumor injection using the MultiAnalyte ELISArray (Qiagen, Limburg, the Netherlands).
Measurement of hemoglobin concentration
Tumor lysates prepared as described above were incubated with Drabkin's reagent (Sigma-Aldrich) and absorbance at 540 nm was measured using a SPECTRAmax 340 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis
In vitro tumor growth is presented as mean AESEM. All data from in vivo experiments are presented as mean AE SD. Tumor in vitro growth comparisons were carried out with Dunnett's t-test. Comparisons between control rat IgG-treated and 2A2B10-treated mice were carried out with the unpaired Student's t-test. All statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA).
Results
Characterization of anti-mouse CLEC-2 monoclonal antibody 2A2B10 and generation of platelet-specific CLEC-2-depleted mice Because CLEC-2-null mice showed embryonic and neonatal lethality [16] , we generated platelet-specific and megakaryocyte-specific conditional CLEC-2-KO (CLEC-2 flox/flox ; Pf4-Cre) mutant mice that survived after birth.
However, these mice were not suitable for investigating the role of CLEC-2 in tumor progression because of blood and lymphatic vessel misconnection and constitutive thrombocytopenia [15, 23] . Therefore, we generated CLEC-2-depleted mice using an anti-CLEC-2 antibody. May et al. showed that CLEC-2 platelet levels can be decreased in vivo by administering anti-CLEC-2 monoclonal antibody, INU1 [14] . INU1-induced CLEC-2 immunodepletion is mediated by Src family kinase-dependent receptor internalization in vitro and in vivo, presumably followed by intracellular degradation [24] . We generated rat anti-mouse CLEC-2 monoclonal antibody, 2A2B10. Western blotting revealed that 2A2B10 recognized a 32-kDa protein in platelet lysates from CLEC-2 +/+ or CLEC-2 +/À mice, but not from CLEC-2 À/À mice (Fig. S1A) . Moreover, flow cytometry results verified that 2A2B10 recognized CLEC-2 on the surface of WT, but not CLEC-2-deficient, platelets (Fig. S1B ). All mice received 2A2B10 (8 lg g À1 body weight) via i.p. injection and circulating platelet levels were assessed at different times. 2A2B10 administration induced transient thrombocytopenia on day 1; however, platelet numbers returned to normal on day 4 after injection ( Fig. 1A) . CLEC-2 was entirely depleted in platelets after 7 days, similar to what has been observed for INU1-treated platelets (Fig. 1B) . A single 2A2B10 injection entirely depleted CLEC-2 in mouse platelets until day 7 (Fig. S1C) . Importantly, 2A2B10 injection did not cause a decrease in levels of other major platelet adhesion molecules (Fig. S1D) . We therefore performed 2A2B10 injections every 7 days. Thrombocytopenia was only induced upon the initial injection, whereas the complete depletion of CLEC-2 in platelets was sustained for 34 days after the initial injection (Fig. 1B) . Next, we examined the effect of 2A2B10 on leukocytes [25] . 2A2B10 injection did not alter CLEC-2 levels on inflammatory NK cells, B cells, macrophages and peripheral neutrophils (Fig. 1C) . Finally, we examined the neutralizing activity of 2A2B10. 2A2B10 injection did not inhibit mPod-rFc2 binding to CLEC-2 on the peripheral neutrophil surface (Fig. 1D) .
Moreover, blood/lymphatic vessel misconnection was not observed in CLEC-2-depleted mice 1 month after the injection (data not shown), consistent with Bender et al. [15] . These results indicate that weekly 2A2B10 injections induced platelet-specific CLEC-2 deficiency without affecting CLEC-2 levels on leukocytes or blood/lymph mixing on days 4-34. The role of CLEC-2 in cancer progression 517
CLEC-2 promotes hematogenous metastasis
Podoplanin inhibition suppresses experimental hematogenous tumor metastasis [20] . However, this does not rule out the existence of a functional podoplanin receptor on the platelet surface as well as CLEC-2. Therefore, we investigated whether CLEC-2 depletion after 2A2B10 injection suppressed experimental hematogenous metastasis in the lungs. Because 2A2B10 induced transient thrombocytopenia after the initial injection (Fig. 1A) , we injected podoplanin-producing mouse melanoma cells transfected with GFP (B16F10-GFP) 4 days after the initial antibody injection (Fig. 2A) . Fluorescence intensity of GFP in the lungs was significantly decreased in CLEC-2-depleted mice (Fig. 2B) . Accordingly, lung weights of CLEC-2-depleted mice were significantly decreased, indicating a reduced number of metastatic foci compared with control mice (Fig. 2C) . These results confirm that the inhibition of CLEC-2-podoplanin interaction suppressed hematogenous metastasis of podoplanin-producing tumor cells.
Because lung metastasis from the tail vein after tumor cell injection is not physiological, we utilized an orthotopic model involving grafting B16F10 cells into dorsal skin. However, we failed to observe spontaneous lung metastasis in the orthotopic model, even in control mice (Fig. S2A) . Notably, we found tumor cells circulating in the ear vessels of control mice 21 days after B16F10 inoculation. Their numbers were significantly reduced in CLEC-2-depleted mice ( Figs 2D and S2B ), suggesting that CLEC-2 may contribute to the survival of CTCs in the blood stream. These results confirm that the inhibition of CLEC-2-podoplanin interaction suppresses hematogenous metastasis of podoplanin-producing tumor cells.
CLEC-2 promotes tumor growth in vitro but not in vivo
Growth factors released during tumor cell-induced platelet aggregation promote tumor growth [26] . We investigated whether CLEC-2 depletion suppressed tumor growth. The proliferation of B16F10 cells co-cultured with CLEC-2-positive platelets from WT mice (Fig. 3A) or control IgG-injected mice (Fig. 3B ) was significantly enhanced, in a platelet dose-dependent manner. However, co-cultures with CLEC-2-deficient platelets from CLEC-2-KO mice (Fig. 3A) or 2A2B10-injected mice (Fig. 3B) did not enhance B16F10 cell proliferation. Co-culture with activated platelet supernatants (Fig. 3C ), but not recombinant CLEC-2 (Fig. 3D) , significantly enhanced B16F10 proliferation, indicating that proliferation is enhanced by granule contents from activated platelets, but not podoplanin-mediated activation signals.
These experiments suggest that tumor growth might be inhibited in vivo in CLEC-2-depleted mice, compared with control IgG-treated mice. Therefore, we injected B16F10 cells s.q. into the control IgG-treated or 2A2B10-treated mice and calculated Tv weekly (Fig. 3E) . However, Tv did not decrease in 2A2B10-treated mice (Fig. 3F) .
CLEC-2 depletion increases density of functional vessels by suppressing thrombus formation in tumors
We next investigated how CLEC-2 depletion suppressed tumor growth in vitro, but not in vivo. We focused on tumor angiogenesis because platelets regulate this process by releasing angiogenic factors [27] . We quantified intratumoral vessels by immunohistochemical staining of CD34 but observed no difference between control rat IgG-treated and 2A2B10-treated mice (Fig. 4A) . Thrombus formation frequently occurs in tumor vessels [28, 29] . CLEC-2 contributes to thrombus stabilization, possibly through homophilic interactions. Accordingly, thrombus formation was decreased in the blood under flow in CLEC-2-deficient mice in comparison with WT mice [16] . Therefore, we hypothesized that CLEC-2 depletion reduced intravascular thrombus formation in tumor tissues. We found that the density of fibrin/fibrinogen-filled tumor vessels was significantly reduced in CLEC-2-depleted mice (Fig. 4B) . Moreover, platelet CD41 colocalized with fibrin/fibrinogen in tumor vessels in control mice, but not CLEC-2-depleted mice (Fig. S3A) . Consistent with this, western blotting showed that CD41 density also decreased in the primary tumors of CLEC-2-depleted mice (Fig. S3B) , further confirming that CLEC-2-depletion inhibits thrombus formation in tumor vessels.
We next investigated whether the reduction in intratumoral thrombus formation increases the density of functional vessels that maintain blood flow. Perfusion with fluorescent dextran revealed that CLEC-2 depletion significantly increased the density of functional intratumoral vessels (Fig. 4C) . Based on these findings, we speculate that CLEC-2 depletion inhibits thrombus formation in tumor vessels, increasing the number of functional vessels and improving oxygen and nutrient supply to tumor tissues, which indirectly facilitates tumor proliferation.
CLEC-2 depletion prolongs the survival of tumor-bearing mice
CLEC-2 depletion suppressed hematogenous metastasis of a B16F10 melanoma injected into the tail vein, but not tumor growth in vivo. We examined whether CLEC-2 depletion improved the overall survival of mice inoculated with B16F10 into the back. We followed the survival of tumor-bearing mice that received control rat IgG or 2A2B10 treatment. Surprisingly, the overall survival of 2A2B10-treated mice was significantly prolonged compared with control IgG-treated mice (Fig. 5A) .
Tumor progression, including distant metastases, and cancer-related thrombosis constitute the two major causes of death of cancer patients [30] . Inoculation of B16F10 cells s.q. did not result in metastasis to the lung, even in the control mice (Fig. S2A) . This result suggests that the prolonged survival of CLEC-2-depleted mice is not due to inhibition of lung metastasis.
Deep vein thromboembolism and pulmonary embolism frequently occur in cancer patients [31] . CLEC-2 depletion suppressed intratumoral vascular thrombosis (Fig. 4B) . Therefore, we hypothesized that CLEC-2 depletion may also reduce a systemic thrombotic tendency. Immunohistochemical analysis revealed that fibrin/fibrinogen clotting in the lungs was significantly reduced 21 days after tumor injection in 2A2B10-treated mice compared with control rat IgG-treated mice (Fig. 5B) . Chronic microembolism leads to inflammation [32] , resulting in cachexia and anemia [33] . Hence, we measured plasma levels of inflammatory cytokines and found that interleukin (IL)-1b, IL-6 and tumor necrosis factor-a (TNF-a) were significantly reduced in 2A2B10-treated mice 21 days after tumor injection (Fig. S4A) . Complete blood count analysis revealed that the control rat IgGtreated tumor-bearing mice developed a more severe anemia than 2A2B10-treated tumor-bearing mice (Fig. S4B) . We also weighed quadriceps femoris muscles as an indicator of cachexia. Quadriceps femoris muscle weights were significantly lower in control mice compared with 2A2B10-treated mice (Fig. S4C) . Together, these findings suggest the possibility that CLEC-2 depletion improved cancer prognosis by suppressing cancer-associated thromboembolism that leads to inflammation, Cell proliferation rate cachexia and anemia, although further study is needed for full elucidation of the mechanism.
Discussion
Our results provide direct evidence for the involvement of CLEC-2 in hematogenous metastasis of podoplanin-producing cancer cells and cancer-associated thrombosis. We found that CLEC-2 depletion suppressed hematogenous tumor metastasis. Furthermore, CLEC-2 depletion improved cancer prognosis, possibly by suppressing thrombus formation in the lungs and subsequent inflammation, anemia and cachexia.
Previously, we showed that anti-podoplanin neutralizing antibody blocks experimental hematogenous metastasis of podoplanin-expressing CHO cells [20] , but whether blocking CLEC-2 inhibits tumor metastasis had not been elucidated. In the present study, we show for the first time that CLEC-2 blockade also inhibits experimental lung metastasis of podoplanin-positive B16F10 cells. We observed that experimental lung metastasis of podoplanin-negative Lewis lung carcinoma cells was not inhibited in bone marrow-specific CLEC-2-deficient chimeric mice (data not shown). Thus together, these results confirm the involvement of CLEC-2 in hematogenous metastasis of podoplanin-expressing tumors. Hematogenous metastasis entails (i) epithelial-mesenchymal transition (EMT), (ii) intravasation, (iii) survival in the blood stream, (iv) extravasation, (v) mesenchymalepithelial transition and (vi) outgrowth of the secondary tumor [34] . The metastasis model with tail vein injection of melanoma cells is only a model for the latter four processes, from survival in the blood to outgrowth of the secondary tumor. We did not observe spontaneous lung metastasis in the orthotopic model, grafting B16F10 cells into the back. However, the number of CTCs in 2A2B10-treated mice was significantly reduced (Fig. 2B) , suggesting that CLEC-2 depletion may inhibit one of the earlier processes, from EMT to survival in the blood. Taken together, it is possible that CLEC-2 depletion inhibits survival of tumor cells in the blood stream.
Co-culturing podoplanin-positive B16F10 cells with WT, but not CLEC-2-deficient, platelets stimulated their proliferation (Fig. 3C) . In contrast, co-culturing podoplanin-negative Lewis lung carcinoma cells with WT platelets did not enhance their proliferation (data not shown), suggesting that platelets stimulated tumor cell proliferation via CLEC-2-podoplanin interaction. Unexpectedly, this direct effect on proliferation was not observed in vivo. Initially, we hypothesized that 2A2B10 was depleting CLEC-2 levels on leukocytes, promoting tumor growth. However, this was not the case because 2A2B10 did not suppress CLEC-2 production and leukocyte CLEC-2-podoplanin binding. Alternatively, solid tumor cells and platelets may not interact directly in vivo as they do in a co-culture. However, tumor vessels are leaky and tumor cells and platelets are frequently in direct contact in solid tumors [35] . In addition, we detected similar intratumoral hemorrhage in both CLEC-2-depleted and control B16F10-injected mice (Fig. S5) .
Next, we hypothesized that CLEC-2 depletion affected the tumor microenvironment, which in turn promoted tumor growth in vivo. Histological analysis revealed that CLEC-2 depletion inhibited thrombus formation in tumor vessels and significantly increased the density of functional vessels maintaining blood flow. Thus, we propose that the increased blood flow improves oxygenation and nutrient supply, possibly promoting tumor growth in vivo. CLEC-2 depletion suppressed the direct tumor-proliferating effect but improved the tumor microenvironment. Therefore, tumor growth in vivo was not significantly different in CLEC-2-depleted and control mice. The 2A2B10-associated increase in functional vessel density may enhance the effect of anticancer drugs by improving drug delivery to cancer cells, and we are currently investigating this possibility.
We observed a significant suppression of thrombus formation in the lungs of 2A2B10-treated mice, indicating that CLEC-2 depletion improved the prothrombotic state in tumor-bearing mice. CTCs induce thrombosis by activating platelets and coagulation [36] . B16F10 cells produce podoplanin and tissue factors [37, 38] that induce platelet activation and thrombin generation, respectively. Tumor-associated platelets protect CTCs from NK elimination. Given these observations, we propose that CLEC-2 depletion suppresses CTC numbers, thereby inhibiting systemic thrombus formation.
Thrombosis facilitates leukocyte migration and inflammation [32] . Tumor-associated macrophages induce TNF-a secretion and initiate inflammation through the NF-jB signaling pathway, inducing IL-1b and IL-6 production [39] . In the present study, IL-1b and IL-6 levels were significantly reduced in CLEC-2-depleted mice compared with control mice. Plasma TNF-a levels in CLEC-2-depleted mice were also lower than in control mice, but the difference was not statistically significant. Chronic inflammation induces thrombosis, forming a positive feedback loop. Chronic inflammation also induces anemia and cachexia, resulting in body weight loss and muscle wasting. Cachexia is closely associated with the quality of life (QOL) of cancer patients and can be treated using anti-TNF-a and anti-IL-6 antibodies [40, 41] . The severity of anemia and cachexia was significantly milder in CLEC-2-depleted mice compared with control mice. Therefore, it is tempting to speculate that CLEC-2 depletion inhibits systemic thrombus formation, subsequently inhibiting inflammation, anemia and cachexia, and prolonging survival and improving QOL of tumor-bearing mice.
A recent meta-analysis showed that aspirin, which blocks cyclooxygenase and platelet activation, inhibited tumor metastasis in adenocarcinoma patients [42] . We speculate that an anti-CLEC-2 drug may have advantages as an anti-metastatic drug. First, an anti-CLEC-2 drug is expected to be associated with lower bleeding tendency [17] , whereas aspirin-treated mice have a higher bleeding tendency [43] . Second, aspirin does not inhibit distant metastasis of cancers other than adenocarcinoma. Podoplanin is produced by several tumor cells, including squamous carcinoma, seminoma, mesothelioma and brain tumor cells, but not by adenocarcinoma cells. Therefore, aspirin and an anti-CLEC-2 drug could be administered to adenocarcinoma patients and patients with podoplaninproducing tumors, respectively. Third, platelet-tumor cell interactions may not be impaired by aspirin, whereas an anti-CLEC-2 drug may directly target these interactions.
In conclusion, we propose that CLEC-2 facilitates tumor progression: although CLEC-2 does not facilitate growth of podoplanin-positive tumors in vivo, it facilitates hematogenous metastasis of podoplaninpositive tumors and systemic thrombus formation, followed by inflammation, anemia and cachexia.
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